Persistence with first line anticholinergic medication in treatment-naïve overactive bladder patients.
about
Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada.OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder.Postmenopausal overactive bladderPersistence with medication and overactive bladder: an ongoing challenge.Clinical and economic impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada.Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long-term extension study.Impact of onabotulinumtoxinA on quality of life and practical aspects of daily living: A pooled analysis of two randomized controlled trials.Is self-reported adherence associated with clinical outcomes in women treated with anticholinergic medication for overactive bladder?A systematic review and meta-analysis of effectiveness and safety of therapy for overactive bladder using botulinum toxin A at different dosages.
P2860
Q33696642-980B0DE9-06C4-4060-848C-008DEA7AF14BQ34804892-E5231F88-1C27-4FEF-8AED-953849FB61D0Q35157329-96A44474-6E88-4F09-9650-495B64C093D0Q38870480-DA36B7D4-9934-4EE3-9FCF-825F7064AABDQ38911819-250FEEE6-A041-43B0-8A96-A0DE9358AB61Q40274618-C5A24337-61A4-46CA-8F75-98535F15D680Q40989355-A9E382F7-0ADA-4C8D-B551-42C356F85B7AQ41725702-A0ECB537-626C-4CD7-B8C9-07B2AE7E74D7Q45788137-DA11B7AA-549E-406B-9518-A5894111A0D2
P2860
Persistence with first line anticholinergic medication in treatment-naïve overactive bladder patients.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Persistence with first line an ...... e overactive bladder patients.
@en
Persistence with first line an ...... e overactive bladder patients.
@nl
type
label
Persistence with first line an ...... e overactive bladder patients.
@en
Persistence with first line an ...... e overactive bladder patients.
@nl
prefLabel
Persistence with first line an ...... e overactive bladder patients.
@en
Persistence with first line an ...... e overactive bladder patients.
@nl
P2093
P2860
P1476
Persistence with first line an ...... e overactive bladder patients.
@en
P2093
David Nemec
Jana Skoupa
Josef Tvrdik
Marcel Gärtner
Martin Petzel
Radek Sykora
P2860
P356
10.3109/21681805.2013.814707
P577
2013-07-22T00:00:00Z